ALB and glioblastoma: As the first study to investigate the co-delivery of ATRA and curcumin via an albumin-based nanoplatform for glioblastoma, this research confirms that protein-based carriers can stand out as a biocompatible and multi-targeted drug delivery platform that effectively enhances the therapeutic potential of the encapsulated agents.